ESCRS - PO0480 - Clinical Evaluation Of An Intraocular Lens Delivery System In Eyes Implanted With Trifocal Diffractive Intraocular Lenses

Clinical Evaluation Of An Intraocular Lens Delivery System In Eyes Implanted With Trifocal Diffractive Intraocular Lenses

Published 2023 - 41st Congress of the ESCRS

Reference: PO0480 | Type: Free paper | DOI: 10.82333/djhf-2j34

Authors: Santiago Tañá-Sanz* 1 , Salvador Aquilar-Córcoles 1 , Pedro Tañá-Sanz 1 , Paz Orts-Vila 1 , José M Rubio 1 , Pedro Tañá-Rivero 1

1Oftalvist,Alicante,Spain

Purpose

 

The objective of the present study was to assess the change of the incision size after the use of the BIOLI-D intraocular lens (IOL) delivery system in eyes implanted with a trifocal diffractive IOL.

Setting

Oftalvist, Alicante, Spain

Methods

60 eyes who underwent implantation with the Asqelio Trifocal IOL TFLIO130C were analyzed at 3 months post-surgery. The main outcome of the study was to measure the incision size intraoperatively before and after the trifocal IOL implantation using the BIOLI-D delivery system. After 1-month post-surgery refractive error and uncorrected and corrected distance visual acuity (UDVA and CDVA) were measured. IOL power and adverse events were also analyzed and reported. This study was approved by Hospital Clínico San Carlos Ethics Committee (Code 22/017_O_P, Madrid, Spain) and registered at www.clinicaltrials.gov.

Results

Refractive astigmatism was distributed randomly before and after the use of the injector and IOL implantation without significant differences (p=0.406 and 0.393 for J0 and J45, respectively). The incision size increased by an average of 0.13mm from the moment the incision was created to the moment immediately after IOL insertion (0.12-0.14 95% limits of agreement, p<0.001). This enlargement occurred in 2 phases, a first enlargement of an average of 0.04mm was reported after phacoemulsification was completed (p<0.001), and a further increase occurred after the IOL was inserted (average 0.09mm, p<0.001). No adverse events occurred at any stage. Similarly, no injector system deficiencies were reported during the surgical procedure.

Conclusions

Enlargement of the incision attributable to the BIOLI-D injector is smaller and more predictable than that reported with other systems, and with little clinical as confirmed by the lack of surgically induced astigmatism, and the good refractive and visual outcomes at 1 month postop.